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Abstract
Ocular hypertension (OHT) is the only known modifiable risk factor of glau-
coma development. Intraocular pressure (IOP)-lowering therapy reduces the risk 
of glaucoma development. The 5-year risk of glaucoma conversion is <10% for 
untreated OHT patients. Cost-effectiveness analyses suggested that it is not cost-
effective to treat all patients with OHT. Treatment should be targeted towards the 
higher-risk group—namely, patients with older age, a higher level of IOP, a thinner 
central corneal thickness (CCT), a larger vertical cup-to-disc ratio (VCDR) and a 
smaller pattern standard deviation (PSD) value on visual field (VF) test. These risk 
factors were established by the Ocular Hypertension Treatment Study (OHTS) and 
the European Glaucoma Prevention Study (EGPS). However, there is significant 
variability in the measurement of the currently known risk factors, especially if the 
assessment is taken from a longitudinal perspective. This can lead to overtreatment 
or under-treatment: the former exposing the patient to unnecessary side effects 
of IOP-lowering eye drops and the latter putting the patient at risk of developing 
glaucoma. The advancement of new VF algorithm and ocular imaging can lead to 
the identification of new approaches to risk stratification and, thus, more specific 
treatment for OHT patients.
Keywords: ocular hypertension (OHT), glaucoma 5-year risk calculator, vertical 
cup-to-disc ratio (VCDR), intraocular pressure (IOP)
1. Introduction
Glaucoma is a leading cause of irreversible blindness worldwide [1]. Subjects 
with ocular hypertension (OHT) are known to have a higher risk of glaucoma devel-
opment. OHT is defined as a mean intraocular pressure (IOP) ≥24 mmHg from two 
separate consecutive measurements without structural and functional evidence 
of glaucoma [2]. Patients with OHT are usually treated with IOP-lowering therapy 
based on the effectiveness of reducing the risk of glaucoma development accord-
ing to the result of the Ocular Hypertension Treatment Study (OHTS) [3], which 
demonstrated a cumulative probability of 9.5% of developing primary open-angle 
glaucoma (POAG) in 5 years in the untreated OHT patients, compared with 4.4% 
in the treated group (patients who received IOP-lowering therapy). Hence, the 
incidence of POAG could be reduced by about 50% with adequate IOP reduction. In 
clinical practice, it is not uncommon that we adopt a treatment approach of liberally 
prescribing IOP-lowering medication based on the study results.
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On the other hand, the result of the OHTS also reflects that only <10% of the 
untreated OHT patients developed glaucoma in 5 years, compared to the 4.4% of 
the treated group. Hence, the number needed to treat to prevent one glaucoma 
development is 20. Indeed, it has been shown that treating all patients with OHT 
is not cost-effective [4, 5]. The estimated incremental cost of treating all OHT 
patients to prevent one subject from developing glaucoma was US$89,072 [4]. 
This is considered not cost-effective according to the standard of The National 
Institute for Health and Care Excellence (NICE), which classified a treatment as 
cost-effective at the level of risk when the incremental cost-effectiveness ratio 
(ICER) is equal to or less than US$50,000 [6]. Furthermore, long-term treatment 
with IOP-lowering medications can impose significant inconvenience and undesir-
able side effects to patients, such as ocular surface disease. For instance, a study 
that involved 537 OHT and POAG patients showed that side effects from medica-
tion can independently contribute to health-related quality of life scores, which 
could be as worse as 0.11 [7]. This is equivalent to the utility loss of patients with 
early to moderate stage of glaucoma [8, 9]. Therefore, selective and targeted use of 
medication is not merely a health economic issue; unnecessarily treating low-risk 
OHT patients would expose them to undesirable medication side effects without 
beneficial gain.
2.  Risk stratification and cost-effectiveness of treating ocular 
hypertension
A more cost-effective approach is to treat OHT subjects who have higher risk of 
developing POAG—namely, an older age, a higher level of IOP, a thinner central 
corneal thickness (CCT), a larger vertical cup-to-disc ratio (VCDR) and a smaller 
pattern standard deviation (PSD) value on visual field (VF) test. These are risk factors 
of POAG development according to the joint data of the OHTS [2] and the European 
Glaucoma Prevention Study (EGPS) [10]. These are the two major multicentre, 
randomised control trials (RCTs) that involved patients with OHT. Stewart et al. 
suggested that it is cost-effective to treat patients with older age (≥76 years old), higher 
intraocular pressure (≥29 mmHg), thinner central corneal thickness (≤533 μm) and 
wider vertical cup-to-disc ratio (≥0.6) [4]. Kymes et al. suggested that treating OHT 
patients with IOP ≥24 mmHg and a ≥ 2% annual risk of glaucoma development is 
likely to be cost-effective [5]. Weinreb et al. suggested a risk stratification strategy: 
observation for patients with lower than average risk of POAG conversion (5-year risk 
of <5%), collaborative treatment decision between doctor and well-informed patient 
for those with moderate risk (5-year risk of 5–15%) and treatment for all subjects with 
higher than average risk (5-year risk of >15%) [11]. Based on this risk stratification 
strategy, it was demonstrated that nearly half (43.9%) of low-risk OHT eyes could 
safely have their medications reduced over 1 year, realising substantial savings [12]. In 
this study, only 1 out of 107 eyes (0.93%) developed a repeatable VF defect in the first 
year [12].
The 5-year risk of POAG development can be calculated using the available 
risk calculator, which was developed based on a predictive model that utilised the 
joint data of OHTS and EGPS [13]. The calculation is based on the risk factors as 
mentioned—age, IOP, CCT, VCDR and PSD value of VF. It has the advantage of 
integrating multiple risk factors into one quantitative, estimated percentage risk 
of glaucoma development in OHT subjects. This can facilitate treatment decision 
because high-risk subjects can be identified based on simultaneous and quantitative 
consideration of all these available risk factors; thus, allows a more straightforward 
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and cost-effective approach of treatment; and reduces unnecessary patient expo-
sure to medication side effects.
3.  Variability of risk factor measurement and the effects on risk 
assessment
It is important to note that, similar to most multivariate prediction models 
derived from prospective studies [14], we are making several assumptions when 
we apply the 5-year risk calculator to guide treatment decision: [1] we assume 
that the baseline variables that were measured are the most predictive of the risk 
of glaucoma development, [2] the model also assumes that the risk of glaucoma 
progression is linear, and [3] patients who are being assessed have similar clinical 
characteristics as the participants in the OHTS and EGPS.
However, the variability of baseline risk factor measurements is a known 
phenomenon. IOP is well known to vary from visit to visit [15], which can be due to 
regression to the mean phenomenon, diurnal variation as well as order of IOP mea-
surement [15]. This variability is also observed in the performance of VF, hence the 
PSD value [16]. Results of VF examination can be affected by patients’ subjectivity 
and the substantial test-retest variability. The PSD value is a weighted standard 
deviation of the differences between the measured and normal reference visual 
field at each test location. A higher PSD value merely suggests a more irregular ‘hill 
of vision’, which can contribute to variability in patients’ responses and/or areas 
of focal loss. Given that, by definition, OHT subjects do not have glaucomatous 
VF defect, the PSD value tends to be low. Therefore, a slight variability in patients’ 
responses can contribute to a significant change in its value. Care must be taken 
when interpreting PSD value as a stand-alone figure.
Therefore, the apparently more comprehensive risk stratification strategy that 
is based on the 5-year risk calculator can face several fundamental challenges. 
As discussed, the variability of IOP measurement and PSD value, even during 
baseline assessment, may add a considerable source of error to the risk calcula-
tion. Furthermore, due to the within-subject changes in risk factors’ values during 
follow-up, the correlation between baseline and updated values may diminish with 
time [17]. One study has demonstrated that risk calculation is variable over time 
and that longitudinal changes in baseline variables correspond with changes in the 
risk estimation of glaucoma development [18]. In the study, the 5-year risk of POAG 
development was calculated by incorporating different measurements that assume 
the best-case scenario (baseline age, lowest PSD, highest CCT and lowest IOP)  
and the worst-case scenario (final age, highest PSD, lowest CCT and highest IOP). 
For the VCDR, a value of ±0.2 was applied to model interobserver and intraobserver 
variability (i.e. -0.2 in addition to the best-case scenario and + 0.2 in addition to 
the worst-case scenario). It was found that, within the same individual, the mean 
risk of POAG conversion could increase by almost 10-fold when comparing the 
worst- and best-case scenarios (5.0% vs. 45.7%, P < 0.01). Hence, risk stratification 
is dynamic, and risk estimations should be recalculated during follow-up visits as 
variables can fluctuate significantly within the same individual over time.
It is important to note that the VCDR data that derived the risk calculator was based 
on VCDR measurements on the optic disc stereophotography of the OHTS and EGPS 
cohorts. In the RCTs, the measurement and evaluation of the optic nerve head (ONH) 
were performed by highly trained, independent graders at designated optic disc cen-
tres that followed a strict protocol in a non-clinical setting [19]. In clinical practice, the 
assessment of ONH and the measurement of VCDR by individual ophthalmologists 
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are susceptible to intraobserver and interobserver variability [20]. The precision and 
quality of the ONH evaluation is unlikely to match those in the RCTs.
Nowadays, imaging technologies such as confocal scanning laser ophthalmos-
copy by Heidelberg retinal tomography (HRT) and optical coherence tomography 
(OCT) provide an objective and reproducible measurement of optic disc parameters. 
However, different techniques of evaluating ONH (hence the VCDR measurement) 
may not agree with each other. For instance, there is a poor agreement in the optic 
disc measurements obtained from HRT and OCT [21]. A study that compared 
VCDR measurement obtained with OCT, HRT and stereophotography in untreated 
OHT patients showed that there were poor agreement and lack of interchange-
ability between different techniques [22]. This is due to the differences between 
Figure 1. 
Optic disc of a normal right eye (a) and corresponding spectral-domain optical coherence tomography 
(OCT, (b)) delineating the anatomical measurements of disc margin. The green dots on the fundus 
photo represent the Bruch’s membrane opening (BMO) identified by spectral-domain optical coherence 
tomography (OCT). The blue crosses represent the disc margin that was identified by an examiner with 
stereophotography. Hence, the green dots and blue crosses represent the potential disc margins that could be 
identified by different examiners (adapted from Chauhan BC and Burgoyne CF 2013 [25]).
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the techniques in defining optic disc margin and optic disc cup. The assessment 
of ONH in HRT and stereophotography relies on the examiners to define the disc 
margin, which can be variable. Spectral-domain OCT demonstrated that the 
‘perceived disc margin’ of HRT and stereophotography rarely correlate with the 
Bruch’s membrane opening (BMO) (Figure 1) [23, 24], which is considered to be 
the true outer border of the neural tissue because axons cannot pass through an 
intact Bruch’s membrane to exit the eye [25]. The BMO is also unaltered under 
larger change of IOP [26]. Hence, it is a more reliable landmark, especially for 
eyes with OHT. Spectral-domain OCT is arguably more accurate in defining the 
ONH because it defines the BMO at every clock hour. It can also reliably identify 
the cup margin by measuring the minimum distance between the BMO and the 
internal limiting membrane in all meridians; the built-in software can then define 
the maximal vertical diameter to be the vertical cup diameter. In comparison, the 
definition of vertical cup diameter by stereoscopic photography and HRT are likely 
to be less accurate. Both are based on subjective judgement of examiners in defin-
ing the cup and disc margin. In some cases of small cups that do not pass through 
the midline of the optic disc, HRT has difficulties in calculating the VCDR because 
it obtains the vertical cup diameter along the vertical axis at the midline of the 
disc. Hence, the value of VCDR becomes ‘0’ if the cup does not pass through the 
vertical midline.
The study that compared VCDR measured by OCT, HRT and stereophotography 
of the ONH in patients with untreated OHT also investigated how the degree of 
disagreement extended to their corresponding 5-year risk estimation when other 
risk factors were kept contant [22]. In the study, ONH images of 140 untreated 
OHT eyes (of 75 patients) were taken by fundus camera (stereoscopic images), 
OCT and HRT. ONH stereophotographs were evaluated with a stereo-viewer by 
two glaucoma specialists, and the VCDR was measured with the ImageJ software. 
VCDR measurements obtained with stereophotography, OCT and HRT were used 
to calculate the estimated 5-year risk. The study showed that there was disagree-
ment in VCDR measurements between the three methods. This disagreement also 
extended to their corresponding 5-year risk estimation of POAG development [22]. 
When the comparison was made on the Bland–Altman plots, the range of discrep-
ancies tended to widen with increasing mean risk, especially beyond the estimated 
Figure 2. 
Bland-Altman plot: comparison of 5-year risk estimations of POAG conversion that were calculated by 
vertical cup-to-disc ratio measured by different vertical cup-to-disc ratio measured by spectral-domain optical 
coherence tomography (OCT) and stereophotography performed by a glaucoma specialist. Notice that the range 
of discrepancies widen with increasing mean risk, especially beyond the estimated risk of >15%. OCT, optical 
coherence tomography; reader 1, stereophotography evaluation (adopted from Chan PP et al., 2019 [22]).
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risk of >15% (Figure 2). We should be careful when using the 5-year risk of >15% 
as our treatment threshold when using VCDR values that are obtained from differ-
ent measurement techniques. This can dramatically alter the management approach 
for any OHT subjects, especially if they have a relatively high baseline estimated 
risk and/or larger VCDR. In the cohort of untreated OHT eyes from this study, up to 
72 eyes (51.2%) would require treatment if OCT was used for assessing the VCDR, 
according to the ≥15% 5-year risk cut-off. On the other hand, only 54 eyes (38.6%) 
would require treatment if the VCDR measurements were obtained from stereopho-
tography by one of the glaucoma specialists. Therefore, one must be cautious when 
applying the risk estimation obtained from the other means of measuring VCDR.
4.  Detection of retinal nerve fibre layer defect and early diagnosis of 
glaucoma
The diagnosis of glaucoma requires a confirmed glaucomatous VF defect that 
correlates with structural change. A glaucomatous visual field loss is defined as a 
cluster of ≥3 non-edged points in the PSD plot in a single hemifield with p value 
<5%, one of which must have a p value <1%; glaucoma hemifield test outside nor-
mal limits; and PSD with p value <5%. Any one of these criteria, if repeatable, was 
considered as sufficient evidence of a glaucomatous VF defect [27]. This has been 
considered as the gold standard of diagnosing glaucoma. OCT has gained popular-
ity in the past decades and is now the standard for assessing structural damage of 
retinal nerve fibre layer (RNFL) and ONH for the detection of structural glaucoma-
tous change. Indeed, RNFL and ONH measured by OCT were shown to be useful 
in differentiating normal eyes from even mild glaucoma [28]. Evidence suggests 
that RNFL thinning measured by OCT can detect glaucomatous damage several 
years before detectable functional deficits by VF testing [28–30]. The 10th World 
Glaucoma Association consensus meeting stated that ‘detecting progressive glauco-
matous RNFL thinning and neuroretinal rim narrowing is the best currently avail-
able gold standard for glaucoma diagnosis [31]’. This emphasised the importance of 
detecting RNFL abnormalities in terms of the diagnosis of glaucoma. Since OCT is 
becoming an invaluable tool for detecting early changes of ONH and RNFL thin-
ning, especially because of its repeatability and objectiveness, it is logical to suggest 
that a risk scoring system for OHT patients should include OCT measurements.
On the contrary, the measurement of VCDR by stereoscopic photography or 
during clinical examination remains the only parameter in the risk calculator that 
reflects the structural status of the complex architecture of the ONH. During the 
slow and progressive process of glaucoma development, enlargement of VCDR 
could happen much later than the occurrence of RNFL thinning and other subtle 
structural glaucomatous damage. It is important to note that the powerful and 
carefully designed OHTS and EGPS were performed in the era when OCT was not 
widely used as an investigative tool. The two studies ruled out glaucoma patients 
from OHT mainly based on VF criteria and the absence of detectable structural 
damage on stereoscopic photography. Therefore, it might not be cavalier to suggest 
that a portion of these subjects might already have ‘asymptomatic disease’ (or pre-
perimetric glaucoma) (Figure 3), and this damage was undetectable on stereoscopic 
photography, which was also suggested by Weinreb et al. [11]. The ever-evolving 
OCT technology and the concepts of ONH assessment can provide valuable data 
and new parameters for further refinement of the existing risk calculator, for 
instance, integrating other factors of OHN and RNFL based on OCT measure-
ment [22]. The glaucoma risk model needs refinement that involves the advancing 
OCT technologies and concepts in measuring VCDR. Reliable risk estimation is 
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important as it may guide treatment decision, which in turn has consequences on 
both health economics and patients’ quality of life.
5. The new trends of early detection of glaucoma and disease progression
5.1 Detecting of RNFL thinning and disease progression
Evidence shows that RNFL abnormalities can often be evident without detect-
able VF damage [32–35]. Therefore, measuring the change of RNFL is likely to be 
useful in detecting early disease progression. Spectral-domain OCT is now the 
invaluable investigation tool for glaucoma patients because it can measure RNFL 
thickness reliably [36] with high sensitivity and specificity to detect glaucoma 
[37, 38] and its progression [39]. Commercially available software event-based 
algorithm, such as the Guided Progression Analysis (GPA, Carl Zeiss Meditec), 
can detect progressive RNFL thinning using RNFL thickness maps. A study has 
demonstrated that GPA can detect and visualise different patterns of progres-
sive RNFL thinning [39]. Trend-Based Progression Analysis (TPA) is another 
algorithm for detecting progressive RNFL thinning by measuring the rate of 
change in RNFL thickness for each superpixel of the RNFL thickness map (50 x 
50 superpixels). A study that involved 139 POAG patients (240 eyes) followed up 
for ≥5 years showed that progressive RNFL thinning determined by GPA and TPA 
was predictive of detectable functional decline in glaucoma. The study showed that 
TPA outperformed GPA in detecting more eyes with progressive RNFL thinning 
at a similar level of specificity (84.2% vs. 81.7% for TPA and GPA, respectively) 
[40]. Furthermore, TPA also provides visualisation of the distribution of the rate 
of RNFL thinning. It was suggested that the detection of progressive RNFL loss 
can serve as a biomarker to reflect disease deterioration behaviour and hence 
guide glaucoma management [40]. However, TPA is not without its limitations. A 
minimum of four follow-up visits is required for the construction of the TPA, and 
performance can be undermined with fewer visits. In situations where there are 
abrupt RNFL changes or in eyes with large test-retest variability, the event-based 
analysis may be more useful [41]. The authors concluded that TPA enhances but 
may not replace GPA for topographic analysis of RNFL thinning.
5.2  The dynamic target IOP, disease progression and quality of life: The LiGHT 
trial
Clinical trials usually define a treatment IOP-lowering target. For instance, the 
OHT study aimed for an IOP lowering by 20% from baseline for patients in the 
treatment arm [3], whereas the Collaborative Normal Tension Glaucoma (CNTG) 
study targeted an IOP lowering by 30% from baseline [42]. The Laser in Glaucoma 
Figure 3. 
Spectrum of disease in glaucoma. RNFL, retinal nerve fibre layer. OCT, optical coherence tomography.  
VF, visual field (adapted from Weinreb et al., 2004 [11]).
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and Ocular Hypertension (LiGHT) trial is a multicentre RCT that compared eye 
drops versus selective laser trabeculoplasty as first-line treatment for POAG or OHT 
[43]. The study is unique with its well-constructed algorithm for detecting disease 
progression and guiding treatment escalation [44]. It has a novel approach to defin-
ing target IOP. Firstly, the target IOP is specific for each patient at baseline, based 
on disease severity and lifetime risk of loss of vision at recruitment (e.g. different 
target pressure and percentage IOP reduction according to the disease stratifica-
tion suggested by Mills et al. [45]). Secondly, the IOP was adjustable based on IOP 
control and disease progression [44]. The disease progression (either glaucoma 
deterioration or conversion of OHT to POAG) was determined by a decision sup-
port software based on objective visual field and optic disc imaging criteria. Disease 
progression was defined as ‘strong evidence’, with the Humphrey GPA software 
showing ‘likely progression’ and/or HRT rim area > 1% per year (at P < 0.001), and 
‘less strong evidence’ with GPA showing ‘possible progression’ and/or HRT rim 
area > 1% per year (at P < 0.01). ‘Likely visual field progression’ is the presence of 
three or more points on the GPA at <0.05 probability for change on three consecu-
tive occasions, while ‘possible visual field progression’ is the same criterion but on 
only two consecutive occasions [44]. Optic disc progression was defined as the rate 
of neuroretinal rim loss exceeding 1% of baseline rim area/year on a minimum of 
five repeat HRT images, where this is equivalent to approximately twice the value 
of normal age-related rim area loss [22]. Following treatment escalation, there is 
a resetting of both the target IOP and visual field and optic disc baselines against 
which future assessments will be compared with.
Although the LiGHT trial is probably more complex in its target IOP setting 
algorithm compared with other glaucoma trials which defined treatment success 
based on the proportion of patients achieving a particular target percentage reduc-
tion of IOP, it resembled closer to our clinical practice. For instance, further IOP 
lowering beyond the ‘target IOP’ is probably required for patients with progressive 
disease. In some cases, patients might request to reduce medication use even when 
the target IOP is not achieved (e.g. OHT patients with IOP at 24 mmHg who do not 
want treatment and show no signs of POAG conversion). Furthermore, the LiGHT 
trial is also unique in that it included the evaluation of quality of life as an outcome 
measure. These are all novel features that might become important components for 
future glaucoma study design.
6. Conclusion
It is more cost-effective to selectively treat OHT subjects who have a higher risk 
of POAG conversion. However, risk assessment can be difficult due to the variabili-
ties in the measurement of the baseline variables of the glaucoma risk calculator. In 
the era of advancing OCT technology and knowledge of glaucoma, there may be a 
need to refine our existing risk assessment methodology.
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